EMA Authorised: Lynparza (olaparib) — AstraZeneca AB

View source ↗

Summary

Olaparib (Lynparza) has been authorised by the EMA for multiple indications across ovarian, breast, pancreatic, and castration-resistant prostatic neoplasms.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Breast Neoplasms
• Ovarian Neoplasms
• Pancreatic Neoplasms
• Prostatic Neoplasms Castration-resistant

Drugs mentioned

• Lynparza (olaparib)

Snippet

Status: Authorised. Therapeutic area: Ovarian Neoplasms;Breast Neoplasms;Pancreatic Neoplasms;Prostatic Neoplasms, Castration-Resistant. MAH: AstraZeneca AB. Decision date: 12/02/2026